hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== Plaque psoriasis === Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.
"For exceptionally meritorious service as Director of Operations, Headquarters North American Aerospace Defense Command, Peterson Air Force Base, Colorado, from May 2005 to August 2008." In 2016, Rear Admiral Mohamed Abdelaziz Elsayed, Egyptian Navy, received the Legion of Merit (Degree of Officer) for “exceptionally meritorious service” as Naval Attaché at the Embassy of Egypt from April 2013 to June 2015, during which he helped improve cooperation and strengthen relations between the U.S. Navy and Egyptian Navy. In 2016, Brigadier General Paul Rutherford, Canadian Army, United States Central Command. "For exceptionally meritorious service as Deputy Director, Strategy, Plans and Policy Military to Military, Strategy, Plans and Policy Directorate, United States Central Command, MacDill Air Force Base, Florida, from August 2013 to August 2015." in 2018, Commodore Alok Bhatnagar, NSM, Indian Navy. "For Exceptionally Meritorious Conduct in the Performance of Outstanding Service as the Indian Naval Attache to United States of America from August 2011 to December 2014. In 2018, Air Commodore A. P. T. Smith (UK). In 2018, Air Commodore Stephen Lushington (UK). For exceptionally meritorious service, NATO Forces, Afghanistan. In 2019, Brigadier General Suzanne Melotte, For exceptionally meritorious service NATO Forces, Afghanistan. In 2021, Major General Matt Holmes Royal Marines (UK). For exceptionally meritorious service and leadership as Deputy Advisor Ministry of Interior, Afghanistan. In 2023, Brigadier General Anoop Shinghal, Sena Medal, (India).
==== Learning ==== Since the seminal studies of Charles Darwin on earthworm intelligence much work has been done on the capacity of earthworms, in particular members of the widespread Lumbricus terrestris, to learn, although some doubts were raised about the use of T-maze experiments for demonstrating learning by earthworms.
Sources: en.wikipedia.org
1991: Doris Malkin Curtis became the first female president of the Geological Society of America. 1991: Indian geologist Sudipta Sengupta became the first female scientist to receive the Shanti Swaroop Bhatnagar Award in the Earth Sciences category. 1991; British chemist and cosmonaut Helen Patricia Sharman became the first woman to visit the Mir space station in May 1991. 1992: American engineer, physician, and NASA astronaut Mae Carol Jemison became the first black woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour. Jemison joined NASA's astronaut corps in 1987 and was selected to serve for the STS-47 mission, during which she orbited the Earth for nearly eight days on September 12–20, 1992. 1992: American chemist Edith M. Flanigen became the first woman awarded the Perkin Medal (widely considered the highest honor in American industrial chemistry) for her outstanding achievements in applied chemistry. The medal especially recognized her syntheses of aluminophosphate and silicoaluminophosphate molecular sieves as new classes of materials. 1993: American molecular biologist and biogerontologist Cynthia Kenyon discovered that a single-gene mutation (Daf-2) could double the lifespan of C. elegans, and that this could be reversed by a second mutation in daf-16m. 1995: German biologist Christiane Nüsslein-Volhard received the Nobel Prize in Physiology or Medicine, shared with Edward B. Lewis and Eric F. Wieschaus, "for their discoveries concerning the genetic control of early embryonic development".
== Awards and honours == 2011 American Chemical Society Cincinnati Chemist of the Year 2015 American Microchemical Society Benedetti Pichler Award 2016 Power List of Top 50 Women Analytical Scientists 2016 Fellow of the Royal Society of Chemistry 2021 The Chromatography Forum of the Delaware Valley Stephen Dal Nogare Award
The thrifty gene hypothesis (also called the famine hypothesis) states that in some populations the body would be more efficient at retaining fat in times of plenty, thereby endowing greater resistance to starvation in times of food scarcity. This hypothesis, originally advanced in the context of glucose metabolism and insulin resistance, has been discredited by physical anthropologists, physiologists, and the original proponent of the idea himself with respect to that context, although according to its developer it remains "as viable as when [it was] first advanced" in other contexts. In 1995, Jeffrey Friedman, in his residency at the Rockefeller University, together with Rudolph Leibel, Douglas Coleman et al. discovered the protein leptin that the genetically obese mouse lacked. Leptin is produced in the white adipose tissue and signals to the hypothalamus. When leptin levels drop, the body interprets this as a loss of energy, and hunger increases. Mice lacking this protein eat until they are four times their normal size. Leptin, however, plays a different role in diet-induced obesity in rodents and humans. Because adipocytes produce leptin, leptin levels are elevated in the obese. However, hunger remains, and—when leptin levels drop due to weight loss—hunger increases. The drop of leptin is better viewed as a starvation signal than the rise of leptin as a satiety signal. However, elevated leptin in obesity is known as leptin resistance. The changes that occur in the hypothalamus to result in leptin resistance in obesity are currently the focus of obesity research.
Micelles form only when the concentration of surfactant is greater than the critical micelle concentration (CMC), and the temperature of the system is greater than the critical micelle temperature, or Krafft temperature. The formation of micelles can be understood using thermodynamics: Micelles can form spontaneously because of a balance between entropy and enthalpy. In water, the hydrophobic effect is the driving force for micelle formation, despite the fact that assembling surfactant molecules is unfavorable in terms of both enthalpy and entropy of the system. At very low concentrations of the surfactant, only monomers are present in solution. As the concentration of the surfactant is increased, a point is reached at which the unfavorable entropy contribution, from clustering the hydrophobic tails of the molecules, is overcome by a gain in entropy due to release of the solvation shells around the surfactant tails. At this point, the lipid tails of a part of the surfactants must be segregated from the water. Hence, they start to form micelles. In broad terms, above the CMC, the loss of entropy due to assembly of the surfactant molecules is less than the gain in entropy by setting free the water molecules that were "trapped" in the solvation shells of the surfactant monomers. Also important are enthalpic considerations, such as the electrostatic interactions that occur between the charged parts of surfactants.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.